Biblio

Doyle TM, Janes K, Chen Z, Grace PM, Esposito E, Cuzzocrea S, Largent-Milnes TM, Neumann WL, Watkins LR, Spiegel S et al..  2020.  Activation of sphingosine-1-phosphate receptor subtype 1 in the central nervous system contributes to morphine-induced hyperalgesia and antinociceptive tolerance in rodents.. Pain. 161(9):2107-2118.

Bartlett MJ, So LY, Szabò L, Skinner DP, Parent KL, Heien ML, Vanderah TW, Polt R, Sherman SJ, Falk T.  2020.  Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model.. BMC Res Notes. 13(1):149.

Thompson AL, Largent-Milnes TM, Vanderah TW.  2019.  Animal Models for the Study of Bone-Derived Pain.. Methods Mol Biol. 1914:391-407.

Khanna R, Patwardhan A, Yang X, Li W, Cai S, Ji Y, Chew LA, Dorame A, Bellampalli SS, Schmoll RW et al..  2019.  Development and Characterization of An Injury-free Model of Functional Pain in Rats by Exposure to Red Light.. J Pain. 20(11):1293-1306.

Hay M, Polt R, Heien ML, Vanderah TW, Largent-Milnes TM, Rodgers K, Falk T, Bartlett MJ, Doyle KP, Konhilas JP.  2019.  A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction.. J Pharmacol Exp Ther. 369(1):9-25.

Chen Z, Doyle TM, Luongo L, Largent-Milnes TM, Giancotti LAntonio, Kolar G, Squillace S, Boccella S, Walker JK, Pendleton A et al..  2019.  Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain.. Proc Natl Acad Sci U S A. 116(21):10557-10562.

Pandit V, Khan M, Zakaria ERasheid, Largent-Milnes TM, Hamidi M, O'Keeffe T, Vanderah TW, Joseph B.  2018.  Continuous remote ischemic conditioning attenuates cognitive and motor deficits from moderate traumatic brain injury.. J Trauma Acute Care Surg. 85(1):48-53.

Lei W, Mullen N, McCarthy S, Brann C, Richard P, Cormier J, Edwards K, Bilsky EJ, Streicher JM.  2017.  Heat-shock protein 90 (Hsp90) promotes opioid-induced anti-nociception by an ERK mitogen-activated protein kinase (MAPK) mechanism in mouse brain.. J Biol Chem. 292(25):10414-10428.

Zissimopoulos JM, Barthold D, Brinton RDiaz, Joyce G.  2017.  Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease.. JAMA Neurol. 74(2):225-232.

Zhang Y, Williams DA, Zaidi SA, Yuan Y, Braithwaite A, Bilsky EJ, Dewey WL, Akbarali HI, Streicher JM, Selley DE.  2016.  17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.. ACS Chem Neurosci. 7(3):297-304.

Zhao L, Mao Z, Woody SK, Brinton RD.  2016.  Sex differences in metabolic aging of the brain: insights into female susceptibility to Alzheimer's disease.. Neurobiol Aging. 42:69-79.

Ramos-Colon CN, Lee YSun, Remesic M, Hall SM, LaVigne J, Davis P, Sandweiss AJ, McIntosh MI, Hanson J, Largent-Milnes TM et al..  2016.  Structure-Activity Relationships of [des-Arg(7)]Dynorphin A Analogues at the κ Opioid Receptor.. J Med Chem. 59(22):10291-10298.

Moutal A, Honnorat J, Massoma P, Désormeaux P, Bertrand C, Malleval C, Watrin C, Chounlamountri N, Mayeur M-E, Besançon R et al..  2015.  CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling.. Cancer Res. 75(17):3519-28.

Deekonda S, Wugalter L, Kulkarni V, Rankin D, Largent-Milnes TM, Davis P, BassiriRad NM, Lai J, Vanderah TW, Porreca F et al..  2015.  Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.. Bioorg Med Chem. 23(18):6185-94.

Giri AKumar, Apostol CR, Wang Y, Forte BL, Largent-Milnes TM, Davis P, Rankin D, Molnar G, Olson KM, Porreca F et al..  2015.  Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.. J Med Chem. 58(21):8573-83.

Majuta LA, Longo G, Fealk MN, McCaffrey G, Mantyh PW.  2015.  Orthopedic surgery and bone fracture pain are both significantly attenuated by sustained blockade of nerve growth factor.. Pain. 156(1):157-65.

Kim J-YV, Tillu DV, Quinn TL, Mejia GL, Shy A, Asiedu MNK, Murad E, Schumann AP, Totsch SK, Sorge RE et al..  2015.  Spinal dopaminergic projections control the transition to pathological pain plasticity via a D1/D5-mediated mechanism.. J Neurosci. 35(16):6307-17.

Fawley JA, Hofmann ME, Largent-Milnes TM, Andresen MC.  2015.  Temperature differentially facilitates spontaneous but not evoked glutamate release from cranial visceral primary afferents.. PLoS One. 10(5):e0127764.

Zhang Y, Braithwaite A, Yuan Y, Streicher JM, Bilsky EJ.  2014.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.. Eur J Pharmacol. 736:124-30.

Hegarty DM, Hermes SM, Largent-Milnes TM, Aicher SA.  2014.  Capsaicin-responsive corneal afferents do not contain TRPV1 at their central terminals in trigeminal nucleus caudalis in rats.. J Chem Neuroanat. 61-62:1-12.

White AG, Watts GS, Lu Z, Meza-Montenegro MM, Lutz EA, Harber P, Burgess JL.  2014.  Environmental arsenic exposure and microbiota in induced sputum.. Int J Environ Res Public Health. 11(2):2299-313.

Hofmann ME, Largent-Milnes TM, Fawley JA, Andresen MC.  2014.  External QX-314 inhibits evoked cranial primary afferent synaptic transmission independent of TRPV1.. J Neurophysiol. 112(11):2697-706.

Bannister K, Lee YSun, Goncalves L, Porreca F, Lai J, Dickenson AH.  2014.  Neuropathic plasticity in the opioid and non-opioid actions of dynorphin A fragments and their interactions with bradykinin B2 receptors on neuronal activity in the rat spinal cord.. Neuropharmacology. 85:375-83.

Largent-Milnes TM, Hegarty DM, Aicher SA, Andresen MC.  2014.  Physiological temperatures drive glutamate release onto trigeminal superficial dorsal horn neurons.. J Neurophysiol. 111(11):2222-31.

Largent-Milnes TM, Brookshire SW, Skinner DP, Hanlon KE, Giuvelis D, Yamamoto T, Davis P, Campos CR, Nair P, Deekonda S et al..  2013.  Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.. J Pharmacol Exp Ther. 347(1):7-19.